Cogent Biosciences Inc (COGT) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Cogent Biosciences Inc stock $16.63, price $27.44, that is 39.4% below the price, quality 35 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Show moreShow less
Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor.
It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Stock analysis
Cogent Biosciences Inc (COGT) currently trades at $27.44, while our estimate is $16.63, 39% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $12.47 (bear) to $20.78 (bull), the price of $27.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Cogent Biosciences Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$329M in FY2025.
Key figures
Market cap $5.8B Mid · EPS (TTM) $−411.92 · Return on equity −99.6% · Return on assets (EBIT) −53.6% (5-year average) · Free cash flow −$266M · Net debt $26.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −39%, COGT screens richer than that median.
Fair Value
Bear$12.47Fair Value $16.63Bull$20.78
Price $27.44 · Downside -39.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality35/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth75
Are margins and returns getting better?
Cashflow20
Do the profits arrive as real cash?
Financial strength100
Debt, balance sheet and risk of trouble
Investment0
Does it invest with discipline instead of growing at any price?
Low Volatility66
How calm the share price moves, does not count
Price momentum20
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, one officer or director sold shares worth $1.7M and none bought.
SaleArlene MorrisDirector45,510 shares at $37.12$1.7MAug 27, 202610b5-1 plan
SaleFairmount Funds Management LLCDirector2× since Jan 22, 2026: 10,500,000 shares, avg. $35.24$370.0MMar 31, 2026
SaleJohn Edward RobinsonChief Scientific Officer90,000 shares at $38.74$3.5MDec 26, 2025
SaleJessica SachsChief Medical Officer82,642 shares at $38.70$3.2MDec 26, 2025
SaleJohn L. GreenChief Financial Officer77,000 shares at $38.68$3.0MDec 26, 2025
SaleEvan KearnsChief Legal Officer65,000 shares at $38.70$2.5MDec 26, 2025
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.19/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−65.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.4%
’15
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−220.8% (2015) → −1,044.3% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
AI conclusion: The business holds a narrow moat yet remains constrained by zero revenue and sharply widening operating losses ahead of commercialization.
Main risk: Extended review times for the three pending FDA decisions could strain the cash runway and pipeline plans before any product revenue arrives.
Cogent Biosciences is increasing spending on commercial teams and launch preparation for bezuclastinib even as it awaits three separate FDA decisions. Losses widened sharply in the latest quarter while the company still generates no product revenue. Will the pending approvals in rare diseases offset the higher burn rate or will extended review times strain the cash runway and pipeline plans?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Below median
Fair Value upside−39.4% · Bottom 25%
Profitability
Return on assets−35.1% · Below median
Balance sheet
Debt / equity0.43× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B9.17× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 36
PAST (return on equity)0· sector 0
HEALTH (low debt)78· sector 96
DIVIDEND (yield)0· sector 21
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Cogent Biosciences Inc (COGT) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $16.63 versus a price of $27.44, about 39% lower (overvalued).
What is the fair value of COGT?
Our estimate for Cogent Biosciences Inc is $16.63 (as of Nov 17, 2026), built from audited fundamentals. The current price: $27.44.
What is the quality score of COGT?
Cogent Biosciences Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cogent Biosciences Inc (COGT)?
Our calculated price target is the estimate of $16.63 (as of Nov 17, 2026). Cautious scenario $12.47, optimistic scenario $20.78. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cogent Biosciences Inc stock forecast for 2026?
Our estimate puts fair value at $16.63, about 39% lower versus a price of $27.44 (overvalued). Cautious scenario $12.47, optimistic scenario $20.78. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Cogent Biosciences Inc (COGT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cogent Biosciences Inc it is $16.63 per share (as of Nov 17, 2026), against a price of $27.44.
Is Cogent Biosciences Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, COGT trades above its calculated fair value: price $27.44, fair value $16.63, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COGT?
No. The price is what the market pays today ($27.44); the fair value is what the company's own numbers justify ($16.63). For Cogent Biosciences Inc the two are $10.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cogent Biosciences Inc worth?
The market values Cogent Biosciences Inc at about $5.8B (market capitalisation, as of Nov 17, 2026). Per share that is $27.44; our models calculate a fair value of $16.63 per share.
What do the bullish and bearish scenarios say about COGT?
Our models span a range for Cogent Biosciences Inc: cautious scenario $12.47, base $16.63, optimistic $20.78 per share (as of Nov 17, 2026, price $27.44). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cogent Biosciences Inc (COGT)?
Balance-sheet figures for Cogent Biosciences Inc (as of Nov 17, 2026): return on equity −99.6%, debt of 0.43 per unit of equity (balance sheet 30 Sep 2026). They feed the Quality Score of 35/100, which uses the fiscal-year figures and measures business quality independently of the share price.
How far is COGT from its 52-week high?
Cogent Biosciences Inc trades at $27.44, about 36% below its 52-week high of $42.84 and at the low of $27.44 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $16.63 is for.
Which stocks are comparable to Cogent Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cogent Biosciences Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $27.44, calculated fair value $16.63 (−39%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Cogent Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cogent Biosciences Inc (COGT)?
The closing price on Nov 16, 2026 was $27.44. Our estimate is $16.63, about 39% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cogent Biosciences Inc right now?
The price sits above even our optimistic bull case ($20.78). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Cogent Biosciences Inc
How large is the market capitalisation of Cogent Biosciences Inc (COGT)?
The market capitalisation of Cogent Biosciences Inc is $5.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Cogent Biosciences Inc (COGT)?
Earnings per share at Cogent Biosciences Inc are $−411.92. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cogent Biosciences Inc (COGT)?
The return on equity (ROE) of Cogent Biosciences Inc is −99.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cogent Biosciences Inc (COGT)?
On an EBIT basis the return on assets of Cogent Biosciences Inc is −53.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Cogent Biosciences Inc (COGT) generate?
The free cash flow of Cogent Biosciences Inc is −$266M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cogent Biosciences Inc (COGT) carry?
The net debt of Cogent Biosciences Inc is $26.8M (balance sheet 30 Sep 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cogent Biosciences Inc in the live analysis
One click puts Cogent Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.